Antibodies taken from alpacas are to be used in a new pandemic flu drug, in a £33 million project led by AstraZenica.

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Screening VHH pairs creates an unbiased pool of antibodies with broader functionality, and through selection of optimal linkers even low-affinity, single-epitope binders function synergistically ...

a trispecific antibody designed as a prophylaxis and therapeutic against SARS-CoV-2 infection. Using in-house phage libraries of naïve and synthetic humanized llama nanobodies (VHH), the Ab ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing P ...

CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca ...

The separated edges of these antibodies are known as VHH antibodies, or nanobodies, which are smaller, easier to modify and more stable. The team has been working on an antibody that can work ...

About VINCOBODIES VINCOBODIES are an advancement in antibody engineering ... the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology.

Humanization of mouse monoclonal antibodies or alpaca nanobody by genetic engineering can increase their similarity to antibodies naturally produced in humans, greatly enhancing their in vivo ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...